GHRP-6: Growth Hormone Releasing Peptide-6 Guide
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Key Takeaways
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that stimulates potent GH release via the ghrelin receptor (GHS-R1a).
It produces the strongest appetite stimulation of any GHRP and generates robust, pulsatile GH pulses, but also elevates cortisol and prolactin at higher doses.
Not FDA-approved for any medical indication, banned by WADA under S2, and sold as a research chemical.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide composed of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates potent growth hormone release by activating the ghrelin receptor (GHS-R1a). Developed in 1984 by American endocrinologist Cyril Y. Bowers, GHRP-6 was the first compound in the GHRP family and the foundation from which all subsequent GH secretagogues — including GHRP-2, hexarelin, and ipamorelin — were derived. It is distinguished from its successors primarily by its pronounced appetite-stimulating effects, the strongest of any GHRP, and its broader hormonal footprint that includes modest elevations in cortisol and prolactin at higher doses.
What Is GHRP-6?
GHRP-6 is a synthetic met-enkephalin analog that was discovered when Bowers and colleagues observed that certain chemical modifications of enkephalin amides produced unexpected growth hormone-releasing activity in pituitary cell cultures. The resulting hexapeptide specifically and dose-dependently released GH both in vitro and in vivo through a mechanism entirely distinct from growth hormone-releasing hormone (GHRH). This was a landmark finding: it demonstrated that a second, independent pathway for GH secretion existed at the pituitary level.
The peptide's amino acid sequence, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, includes two D-amino acids (D-Trp and D-Phe), which confer resistance to enzymatic degradation and contribute to its receptor binding affinity. Its molecular formula is C46H56N12O6 with a molecular weight of 873.0 g/mol.
GHRP-6 acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), which was later identified as the ghrelin receptor after Kojima and colleagues discovered ghrelin as its endogenous ligand in 1999. This makes GHRP-6 a functional ghrelin mimetic. It activates the same receptor that the body's primary hunger hormone acts on, which explains its potent orexigenic (appetite-stimulating) effects.
What sets GHRP-6 apart from newer GHRPs is this appetite stimulation. While GHRP-2 and ipamorelin produce similar GH elevations with minimal hunger, GHRP-6 triggers intense appetite within minutes of administration. This characteristic may be beneficial for individuals seeking to increase caloric intake (such as in clinical wasting scenarios) but is often unwanted in body composition optimization protocols.
Proposed benefits of GHRP-6 include:
Robust stimulation of endogenous growth hormone release
Increased appetite and caloric intake
Enhanced lipolysis and improved body composition over time
Accelerated recovery from exercise and injury
Potential cardioprotective and cytoprotective properties (preclinical evidence)
Improved sleep quality via amplified nocturnal GH pulses
Increased collagen synthesis and connective tissue repair
How It Works
Ghrelin Receptor (GHS-R1a) Activation
GHRP-6 binds to the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland and on hypothalamic neurons in the arcuate nucleus. Upon binding, GHRP-6 activates Gq/11 protein coupling, which stimulates phospholipase C (PLC) activity. PLC generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release from the endoplasmic reticulum, which initiates GH exocytosis from secretory granules.
GHRP-6 also binds to the ectodomain of the CD36 receptor, a scavenger receptor involved in lipid metabolism and immune signaling. This secondary binding site may underlie some of the peptide's reported cytoprotective and anti-inflammatory properties observed in preclinical models, though the clinical significance remains under investigation.
Growth Hormone Release Mechanism
At the pituitary level, GHRP-6 directly stimulates somatotroph cells to release stored GH in a dose-dependent manner. The resulting GH pulse is rapid and robust: peak plasma GH concentrations typically occur within 15 to 30 minutes of subcutaneous injection, with the pulse lasting approximately 60 to 90 minutes.
Critically, endogenous GHRH is required for most of the GH response to GHRP-6. Research by Leal-Cerro and colleagues demonstrated that in patients with hypothalamic-pituitary disconnection, GHRP-6's ability to release GH is severely blunted. This indicates that GHRP-6 works both directly on the pituitary and indirectly through hypothalamic GHRH neurons, and the two pathways function synergistically. This synergy is the pharmacological basis for stacking GHRP-6 with GHRH analogs such as CJC-1295.
Appetite and Ghrelin Pathway Effects
Because GHS-R1a is the same receptor activated by endogenous ghrelin, the body's primary hunger-signaling hormone, GHRP-6 stimulates appetite through identical hypothalamic pathways. The peptide activates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus, which drive feeding behavior.
The appetite effect is not a consequence of hypoglycemia. Blood glucose studies following GHRP-6 administration have not shown hypoglycemic readings; the hunger is a direct central nervous system effect of ghrelin receptor activation. GHRP-6 produces the most intense appetite stimulation of any synthetic GHRP, substantially more than GHRP-2 and far more than ipamorelin, which produces negligible hunger at standard doses.
Cortisol and Prolactin Considerations
Unlike ipamorelin, which selectively releases GH without affecting other pituitary hormones, GHRP-6 has a broader activation profile. At standard doses of 100 mcg or below, cortisol and prolactin elevations are generally minimal. However, at doses above the saturation threshold (approximately 1 mcg/kg), GHRP-6 stimulates adrenocorticotropic hormone (ACTH) release, leading to elevated cortisol, and increases prolactin secretion from lactotroph cells.
These effects are dose-dependent and transient, typically normalizing within hours. However, chronically elevated cortisol can promote fat storage, impair immunity, and disrupt sleep, while sustained prolactin elevation can cause gynecomastia and reproductive effects in sensitive individuals. This is a key reason dosing should remain at or below the saturation threshold.
Dosage Protocols
No FDA-approved dosing guidelines exist for GHRP-6. The following protocols are derived from clinical research and community experience:
Saturation Dose Concept: The saturation dose for GHRP-6 is approximately 1 mcg/kg of body weight, which translates to roughly 100 mcg per injection for a 100 kg individual. Doses beyond this point do not proportionally increase GH release but do escalate cortisol and prolactin co-secretion. This makes the saturation dose the optimal ceiling for each individual injection.
Beginner Protocol
100 mcg once or twice daily (morning and bedtime), for 8 to 12 weeks. The bedtime dose is the priority, as it amplifies the natural nocturnal GH surge.
Intermediate Protocol
100 mcg two to three times daily (morning, midday, bedtime), for 8 to 12 weeks. Each injection should be separated by at least 3 hours to allow GH pulsatility to normalize between doses.
Advanced Protocol
100 to 150 mcg three times daily, often combined with a GHRH analog such as CJC-1295 (Mod GRF 1-29) at 100 mcg per injection, for 12 to 16 weeks.
Cycling Recommendations
Cycling is recommended: 8 to 16 weeks on followed by 4 to 8 weeks off. See the peptide cycling guide for structured protocols. Prolonged continuous use beyond 16 weeks may result in diminishing GH response due to receptor desensitization. Rotating to another GHRP (such as GHRP-2 or ipamorelin) during off-cycles is a common strategy.
How to Use / Administration Methods
GHRP-6 is administered via subcutaneous injection, typically into abdominal fat, the thigh, or the deltoid region.
Timing is critical. GHRP-6 should be injected on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal. Elevated blood glucose and insulin significantly blunt the GH response. Given GHRP-6's intense appetite stimulation, most users eat their meal 20 to 30 minutes post-injection, effectively using the peptide as a pre-meal trigger.
Injection process:
Reconstitute the lyophilized powder with bacteriostatic water (see Reconstitution section below)
Draw the appropriate dose into an insulin syringe (29 to 31 gauge)
Pinch a fold of skin at the injection site
Insert the needle at a 45 to 90 degree angle
Slowly depress the plunger
Hold for 5 seconds before withdrawing; dispose of the needle properly
Injection sites should be rotated to prevent lipodystrophy. The pre-bed injection is widely considered the most important administration window, as it amplifies the body's largest natural GH pulse during deep sleep.
Results Timelines
The following timeline is based on community reports and clinical observations rather than controlled trials. Individual results vary considerably.
Weeks 1 to 2:
Markedly increased appetite within minutes of each injection
Improved sleep quality and deeper rest
Some users report more vivid dreams
Weeks 3 to 4:
Faster recovery from exercise and reduced delayed-onset muscle soreness
Mild water retention and increased skin fullness
Subtle improvement in energy levels
Weeks 6 to 8:
Body composition changes become more visible, gradual reduction in subcutaneous fat and improved muscle fullness
Skin quality improvements, including increased hydration
Joint comfort improvements from enhanced collagen synthesis
Weeks 10 to 12:
More significant body composition shifts with consistent training and nutrition
Strength and recovery gains become more pronounced
Hair and nail growth improvements are sometimes reported
Weeks 12 to 16+:
Cumulative benefits reach their peak
Appetite stimulation typically remains consistent and does not diminish
GH response may begin to plateau; this is when cycling off is recommended
Individual responses vary considerably based on age, baseline GH levels, training status, diet, and genetics.
Research Evidence
Growth Hormone Stimulation Studies
The foundational 1984 study by Bowers and colleagues in Endocrinology demonstrated that GHRP-6 specifically elicited a dose-dependent release of GH in vitro and in vivo without concomitant release of LH, FSH, TSH, or prolactin at standard doses. Subsequent work established the saturation dose of approximately 1 mcg/kg IV, producing peak GH levels of 15 to 50 mcg/L in healthy subjects.
Oral Administration in Children
A 1995 study by Bellone and colleagues published in the European Journal of Endocrinology demonstrated that oral GHRP-6 retained GH-releasing activity in children with short stature. In 13 children aged 6.2 to 10.5 years, oral GHRP-6 induced a GH response with peak values of 18.8 mcg/L at 60 minutes, comparable to that elicited by intravenous GHRH. This result warrants caution: oral bioavailability of hexapeptides is generally very low due to gastrointestinal degradation and poor intestinal absorption, and the finding has not been widely replicated or supported by pharmacokinetic data confirming systemic absorption at meaningful levels.
Cortisol and ACTH Effects
Pena-Bello et al. (2010) studied the effects of GHRP-6, GHRH, and their combination on GH, ACTH, and cortisol in patients with type 1 diabetes mellitus. The research confirmed that GHRP-6 produces modest but measurable ACTH and cortisol elevations alongside GH release, particularly at doses above the saturation threshold.
Cardioprotective Research (Preclinical)
A significant body of preclinical research from Cuban investigators has documented cardioprotective and cytoprotective properties of GHRP-6. Berlanga-Acosta et al. (2006) demonstrated that GHRP-6 reduced myocardial necrosis by 78% and infarct thickness by 50% in a porcine model of acute myocardial infarction, acting through oxidant-scavenging mechanisms.
More recently, Sosa-Hernandez et al. (2024) showed that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage in rats by attenuating pro-oxidant activity, enhancing antioxidant reserves, protecting mitochondrial ultrastructure, and upregulating the anti-apoptotic gene Bcl-2. The cytoprotective effects extended beyond the heart to hepatocytes, renal tubular cells, bronchial epithelia, and intestinal enterocytes.
Pharmacokinetic Profile
Fernandez-Perez et al. (2013) conducted a formal pharmacokinetic study in nine healthy male volunteers, establishing a biphasic profile: a rapid distribution phase of approximately 7.6 minutes followed by an elimination phase of approximately 2.5 hours. Peak GH levels occurred within 15 to 30 minutes of administration. This biphasic profile necessitates multiple daily injections for sustained GH elevation.
Stacking
GHRP-6 + CJC-1295 (Mod GRF 1-29)
This is the classic GH secretagogue stack and the most widely used combination. CJC-1295 (without DAC), also called Mod GRF 1-29, is a GHRH analog that activates GHRH receptors on the pituitary. When combined with GHRP-6, the two compounds activate complementary pathways: GHRH primes and sustains the GH release signal while GHRP-6 amplifies the pulse amplitude. Preclinical and clinical data suggest this combination produces substantially greater GH elevations than either compound alone, though the precise magnitude has not been characterized in controlled human trials.
A typical protocol involves 100 mcg of each peptide administered simultaneously via separate subcutaneous injections (or reconstituted in the same syringe), two to three times daily. The synergy means lower individual doses can be used while achieving greater total GH output.
GHRP-6 + GHRH Analogs (General)
The same synergistic principle applies to any GHRH analog, including tesamorelin and sermorelin. The GHRP-6 component provides the acute GH pulse amplification while the GHRH analog provides the sustained baseline elevation.
GHRP Rotation Strategies
Some users rotate between GHRP-6 and other GHRPs (GHRP-2, ipamorelin) within a cycle to manage appetite effects. The peptide stacking guide covers rotation strategies in more detail. For example, using GHRP-6 at pre-meal windows (where the appetite stimulation is welcome) and ipamorelin for the bedtime dose (where hunger before sleep is undesirable).
Reconstitution, Storage & Prep
GHRP-6 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use.
Reconstitution Process:
Allow the peptide vial and bacteriostatic water to reach room temperature
Using a sterile syringe, draw the desired volume of bacteriostatic water (typically 2.5 mL for a 5 mg vial)
Inject the water slowly against the vial wall, allowing it to run down gently. Do not spray directly onto the powder
Swirl gently until fully dissolved; never shake, as this can denature the peptide
The solution should be clear and colorless; discard if cloudy or particulate
Dosing Calculation Example:
If reconstituting 5 mg with 2.5 mL bacteriostatic water, the concentration is 2 mg/mL (2000 mcg/mL). For a 100 mcg dose, draw 0.05 mL (5 units on a standard U-100 insulin syringe).
Storage Guidelines:
Unreconstituted powder: Stable at room temperature for months; refrigeration extends shelf life to 12 or more months
Reconstituted solution: Refrigerate at 2 to 8 degrees C (36 to 46 degrees F); use within 28 days
Never freeze reconstituted peptides
Protect from light and heat
Use bacteriostatic water (containing 0.9% benzyl alcohol) rather than sterile water for multi-dose vials to prevent bacterial contamination
Side Effects
GHRP-6's side effect profile is more pronounced than newer, more selective GHRPs like ipamorelin, though most effects are dose-dependent and transient.
Common:
Intense hunger and appetite stimulation (onset within 15 to 20 minutes of injection, lasting 30 to 60 minutes). This is the most frequently reported effect and is inherent to GHRP-6's mechanism
Mild water retention and peripheral edema, particularly during the first 2 to 4 weeks
Transient flushing, warmth, or dizziness immediately post-injection
Injection site reactions (redness, minor swelling)
Less Common:
Tingling or numbness in the extremities (hands and feet), related to GH-mediated fluid shifts
Head rush or lightheadedness shortly after administration
Drowsiness, particularly with evening doses
Dose-Dependent (above saturation dose):
Elevated cortisol via ACTH stimulation. Chronic elevation can impair fat loss, disrupt sleep, and suppress immune function
Elevated prolactin. In sensitive individuals, sustained elevation may cause gynecomastia or reproductive effects
These hormonal effects are generally not observed at doses of 100 mcg or below
Theoretical/Long-Term:
Potential effects on glucose metabolism and insulin sensitivity with prolonged use
As with all GH-elevating compounds, theoretical concern regarding promotion of growth in undiagnosed malignancies
Water retention and tingling typically diminish within the first few weeks as the body adapts. Starting at a lower dose and titrating upward can minimize initial discomfort.
Legal Status / FDA
GHRP-6 is not FDA-approved for any human medical indication. It is not the subject of a USP or NF monograph, is not a component of any FDA-approved drug product, and does not appear on the 503A bulk drug substance list for compounding pharmacies.
GHRP-6 remains available for purchase as a research chemical from suppliers serving academic and industrial laboratories. Selling it as a dietary supplement, therapeutic agent, or for human consumption is prohibited. Possession for personal use is not explicitly criminalized under federal law in the United States, but regulations vary internationally.
In Australia, GHRP-6 is classified as a Schedule 4 prescription-only substance. Similar restrictions apply in the United Kingdom and the European Union. Users should verify their specific jurisdiction's regulations, as the legal landscape for peptides continues to evolve.
Sports / WADA
The World Anti-Doping Agency (WADA) explicitly prohibits GHRP-6 under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the Prohibited List. The prohibition applies both in-competition and out-of-competition. GHRP-6 is listed by name alongside GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5, hexarelin (examorelin), and alexamorelin.
This prohibition extends to all sports and organizations that have adopted the World Anti-Doping Code, including the International Olympic Committee, national anti-doping agencies, and most professional and collegiate athletic organizations. Detection methods for GHRPs have improved substantially, and metabolites can be identified in urine samples for several days after administration.
Any athlete subject to anti-doping testing should assume that GHRP-6 use will result in a positive test and subsequent sanctions, including suspension, forfeiture of results, and potential career consequences.
Conclusion
GHRP-6 holds a unique place in peptide pharmacology as both a historical landmark and a practical tool. It was the founding member of the GHRP family — the peptide that ultimately led to the discovery of the ghrelin receptor and the endogenous hormone ghrelin itself. Its robust GH-releasing activity is well-documented across decades of research, and its preclinical cardioprotective profile remains one of the most intriguing areas of ongoing investigation.
However, GHRP-6's pronounced appetite stimulation and broader hormonal footprint, including cortisol and prolactin elevation at higher doses, make it a less refined option than newer secretagogues like ipamorelin. It is best suited for individuals who welcome appetite stimulation or who combine it with GHRH analogs in structured stacking protocols where its synergistic GH-amplifying properties are maximized.
As with all unapproved peptides, users should approach GHRP-6 with clear awareness of its regulatory status, the limitations of current human safety data, and the importance of sourcing from reputable suppliers with verified certificates of analysis. Consultation with a knowledgeable healthcare provider is strongly recommended.
Frequently Asked Questions
Both are hexapeptide GH secretagogues acting on the ghrelin receptor, but GHRP-6 produces significantly stronger appetite stimulation. GHRP-2 is considered slightly more potent for GH release per microgram and causes less hunger, making it the preferred choice when appetite is unwanted.
Yes. GHRP-6 produces the most pronounced appetite stimulation of any GHRP, often described as intense hunger within 15 to 20 minutes of injection. This effect is mediated directly through ghrelin receptor activation in the hypothalamus and is not caused by hypoglycemia.
The commonly cited saturation dose is approximately 1 mcg/kg of body weight, which translates to roughly 100 mcg per injection for most adults. Doses are typically administered two to three times daily on an empty stomach. Exceeding the saturation dose does not proportionally increase GH release but does elevate cortisol and prolactin.
The most common side effect is intense hunger shortly after injection. Other effects include mild water retention, transient flushing or dizziness, and tingling in the extremities. At doses above the saturation threshold, GHRP-6 can elevate cortisol and prolactin levels. These effects are generally dose-dependent and transient.
Ipamorelin is more selective, releasing GH without meaningfully affecting cortisol, prolactin, or appetite at standard doses. GHRP-6 produces a comparable GH pulse but with significant appetite stimulation and modest cortisol and prolactin elevation. Ipamorelin is generally preferred for cleaner side effect profiles, while GHRP-6 may suit those seeking appetite stimulation.
GHRP-6 is not FDA-approved for human use and cannot be legally sold as a therapeutic or dietary supplement. It is available for purchase as a research chemical in many jurisdictions. It is banned by WADA in all competitive sports. Legal status varies by country, so users should verify local regulations.
GHRP-6 is administered via subcutaneous injection, typically into abdominal fat, the thigh, or the deltoid. It should be injected on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal, as elevated insulin blunts GH release. The most common protocol is two to three injections daily.
GHRP-6 elevates endogenous growth hormone, which supports protein synthesis, recovery, and lean body composition over time. However, the GH elevations from GHRP-6 are modest compared to exogenous HGH, and meaningful body composition changes typically require consistent use over 8 to 12 weeks alongside proper training and nutrition.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
Leal-Cerro A, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
Pena-Bello L, et al. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. Metabolism. 2010;59(11):1536-1542.
Bellone J, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-430.
Sosa-Hernandez JL, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024;15:1402138.
Berlanga-Acosta J, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-250.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
World Anti-Doping Agency. The Prohibited List.
Fernandez-Perez L, et al. Pharmacokinetic study of growth hormone-releasing peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46.
See Related Peptides
GHRP-2
GHRP-2 is the most potent GHRP with a cleaner profile than GHRP-6. Learn about its mechanism, dosage protocols, side effects, stacking, and legal status.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone analog that stimulates the pituitary to produce GH and IGF-1. Learn about uses, dosage protocols, side effects, legal status, and research evidence.
Ipamorelin
Ipamorelin: Selective GH secretagogue for enhanced body composition, recovery, and anti-aging. Doses 200-300mcg 1-3x daily. Minimal side effects, safe & well-tolerated.
Related Guides
Best Peptides for Muscle Growth
Compare the best peptides for muscle growth, recovery, and body composition. Evidence-based rankings of CJC-1295, Ipamorelin, GHRP-6, Sermorelin, and more.
Peptide Stacking Guide
Peptide stacking combines two or more peptides in coordinated protocols to achieve synergistic effects for muscle growth, fat loss, recovery, and cognitive enhancement. Learn the most effective stacks, dosing strategies, safety protocols, and monitoring guidelines.
Peptide Cycling
Learn when and why to cycle peptides. Understand cycling protocols for growth hormone secretagogues, healing peptides, and metabolic peptides to optimize results and avoid tolerance.